FarEye Launches Grow – A Game-changing Self-Serve Merchant Portal for Logistics Companies to Accelerate Customer Acquisition and Drive Growth
11.5.2023 17:00:00 EEST | Business Wire | Press release
FarEye today announced Grow, a solution for logistic companies to provide a modern-age experience to its customers. With a user-friendly interface, frictionless onboarding, automated booking, and seamless payments integration, Grow is set to empower logistics businesses to accelerate customer acquisition, improve customer satisfaction, and drive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005538/en/
Grow is a cutting-edge self-serve merchant portal designed to revolutionize the way logistics companies manage their shipping operations. (Photo: Business Wire)
With the parcel delivery market projected to hit $200 billion by 2026 and over tens of millions of shippers worldwide, it's clear that logistic companies have an unprecedented opportunity for growth. Every retailer and e-commerce company wants to offer home delivery but continues to struggle to find the right, modern-age logistics partner and are stuck with legacy ways of home delivery. Grow enables logistics companies to address this demand-supply gap.
"We are thrilled to launch Grow, which we believe will become an indispensable tool for logistics companies seeking to acquire new retailers and stay ahead of the competition," said Kushal Nahata, CEO of FarEye. "Our team has worked tirelessly to create a platform that unlocks the potential of thousands of logistic companies, and we are confident that Grow will transform the way logistics businesses interact with their customers and manage their day-to-day operations."
FarEye Grow is an easy way for merchants to self-serve, get quotes, create orders, generate labels, and manage transactions. It also offers shipment-level visibility and in-built exception management, enabling retailers and shippers to save time and effort, leading to increased customer satisfaction. In addition, automated invoice generation and payments with digital wallet capabilities allow logistic companies to reduce payment delays and improve cash flow. Grow is equipped with built-in plug-ins with major e-commerce platforms like Shopify and BigCommerce, allowing shippers to connect and start delivering quickly.
FarEye Grow is a part of the FarEye product portfolio that supports companies through the complete order-to-door delivery journey. It has products like Ship, Track, Route, Execute, Experience, Analyze, and now, Grow, which offers the following key benefits:
- Personalized portal for easy onboarding: Allows self-onboarding and complete order entry, get quotes, generate labels, real-time status updates, and proof of delivery on one platform.
- Track and trace visibility: Provides real-time track and trace visibility and address validation to merchants for booked orders.
- Scale with your merchants: Track merchants’ growth, run campaigns based on orders and transactions, and make recommendations for merchants to transact more for revenue and business growth.
- Booking order transparency: Self-service merchant order booking directly from the platform, this helps CEPs track revenue and reduce lost revenue.
- Digital wallet management: Offer customers purchase credit for their shipping needs. Provide complete visibility into all transactions, book and pay for shipments by multiple payment modes, including directly by wallet.
FarEye's Grow is the ultimate customer portal for CEP companies looking to streamline shipping operations, expand their customer network, and achieve sustainable growth in today's competitive industry. To learn more about the portal and how it can benefit your business, visit the FarEye website today.
About FarEye
FarEye’s Delivery Management platform turns deliveries into a competitive advantage. Retail, e-commerce and third-party logistics companies use FarEye’s unique combination of orchestration, real-time visibility, and branded customer experiences to simplify complex last-mile delivery logistics. The FarEye platform allows businesses to increase consumer loyalty and satisfaction, reduce costs and improve operational efficiencies. FarEye has 150+ customers across 30 countries and five offices globally. FarEye, First Choice for Last Mile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005538/en/
Contact information
PR Contact:
Bradford Peirce, Industry Strategy Executive, bradford.peirce@fareye.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom